Market Access Anglonordic Life Science 2026: A focus on execution The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
News After rival fails, Cytokinetics could broaden Myqorzo label Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.
News Amgen, AZ will pilot FDA's real-time clinical trial plan The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
News Boehringer/Zealand dual-acting drug causes 16.6% weight loss Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.
News Intellia files CRISPR drug after historic phase 3 readout Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.
R&D The devil’s in the details: Navigating complexity & nuance i... Clinical trial expansion comes with complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations.
News Biogen, Denali pull Parkinson's drug after failed trial Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
